Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.

Family history of cancer ups risk of testicular cancer in children, young adults

17 Apr 2019

A family history of testicular cancer (TC), carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant neuroepithelial tumours appears to increase the risk of paediatric and young adults’ TC, suggests a recent study.

A significant association was found between a history of TC in male relatives and a diagnosis of TC among children and young adults, including brothers (6.3-fold), sons (4.7-fold), fathers (4.4-fold), paternal uncles (2.0-fold) and maternal uncles (1.9-fold).

Risk was also elevated among individuals with a father diagnosed with a carcinoma (1.1-fold) or sarcoma (1.8-fold). A family history of mesothelioma positively correlated with a risk of TC (father, 2.8-fold; mother, 4.6-fold; and maternal uncles and aunt, 4.4-fold).

In addition, siblings diagnosed with malignant melanoma had increased risks of TC (1.4-fold). A diagnosis of malignant neuroepithelial tumours in fathers (11.1-fold), paternal (4.9-fold), and maternal uncles and aunts (4.6-fold) also increased the risk of TC.

“Hereditary cancer syndromes might underlie some of the associations reported in this study,” the investigators said.

These findings are consistent with those of a previous study, which reported that sons and brothers of TC patients are at higher risk of developing this cancer at an age close to the age at diagnosis of their relatives. [Eur Urol 2015;68:283-289]

The present prospective cohort study examined the association of a family history of cancer with the risk of TC in young adults and included 1,974,287 males born 1951–2015. Of the participants, 2,686 were diagnosed with TC before the age of 30.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.